Healthcare Costs for Metastatic Castration Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide in the Pre and Post Chemotherapy Setting

Rana, D. et al. (2020) Healthcare Costs for Metastatic Castration Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide in the Pre and Post Chemotherapy Setting. EUHEA 2020, Oslo, Norway, 7-10 July 2020 [Event cancelled].

Full text not currently available from Enlighten.

Abstract

No abstract available.

Item Type:Conference or Workshop Item
Additional Information:Conference cancelled. Virtual Conference held 9 July 2020.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Rana, Miss Dikshyanta and Wu, Professor Olivia and Geue, Dr Claudia and Jones, Professor Robert
Authors: Rana, D., Geue, C., Baillie, K., Pan, J., Mueller, T., Laskey, J., Bennie, M., Clarke, J., Jones, R. J., Brown, A., and Wu, O.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record